New drug combo aims to outsmart Treatment-Resistant head and neck cancer

NCT ID NCT04966481

Recruiting now Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding palbociclib to cetuximab helps people with a certain genetic type of head and neck cancer live longer than cetuximab alone. Participants must have HPV-unrelated cancer with a CDKN2A gene change that has worsened after prior immunotherapy. About 81 adults will receive either the combination or single drug, and researchers will compare survival and tumor response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV-UNRELATED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

Saint Luke's Hospital
WITHDRAWN

Kansas City, Missouri, 64111, United States
Sanford Medical Center
RECRUITING

Sioux Falls, South Dakota, 57104, United States
Sanford Roger Maris Cancer Center
RECRUITING

Fargo, North Dakota, 58122, United States
Sanford Worthington Medical Center
NOT_YET_RECRUITING

Worthington, Minnesota, 56187, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States